Aerpio Pharmaceuticals Inc (ARPO) Stock Price, Forecast & Analysis
NASDAQ:ARPO
ARPO Key Statistics, Chart & Performance
The current stock price of ARPO is 2.2 null. In the past month the price increased by 3.77%. In the past year, price increased by 65.41%.
ARPO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARPO. When comparing the yearly performance of all stocks, ARPO is one of the better performing stocks in the market, outperforming 85.4% of all stocks.
ARPO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARPO. ARPO has a great financial health rating, but its profitability evaluates not so good.
ARPO Financial Highlights
Over the last trailing twelve months ARPO reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -355.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ARPO Forecast & Estimates
2 analysts have analysed ARPO and the average price target is 47.94 null. This implies a price increase of 2079.09% is expected in the next year compared to the current price of 2.2.
For the next year, analysts expect an EPS growth of 33.81% and a revenue growth -100% for ARPO
ARPO Ownership
ARPO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.56 | 981.56B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 589.194B | ||
| MRK | MERCK & CO. INC. | 22.57 | 295.956B | ||
| PFE | PFIZER INC | 9.26 | 156.186B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 121.86B | ||
| ZTS | ZOETIS INC | 18.77 | 55.368B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.73 | 25.86B | ||
| VTRS | VIATRIS INC | 6.25 | 18.186B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.23 | 12.317B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.35 | 9.222B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARPO
Company Profile
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Loveland, Ohio and currently employs 12 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The firm is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The firm's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Company Info
Aerpio Pharmaceuticals Inc
10663 LOVELAND-MADEIRA ROAD #168
Loveland OHIO 45242 US
CEO: Joseph Gardner
Employees: 12
Phone: 15139851920.0
Aerpio Pharmaceuticals Inc / ARPO FAQ
Can you describe the business of Aerpio Pharmaceuticals Inc?
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Loveland, Ohio and currently employs 12 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The firm is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The firm's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Can you provide the latest stock price for Aerpio Pharmaceuticals Inc?
The current stock price of ARPO is 2.2 null. The price decreased by -0.9% in the last trading session.
Does Aerpio Pharmaceuticals Inc pay dividends?
ARPO does not pay a dividend.
How is the ChartMill rating for Aerpio Pharmaceuticals Inc?
ARPO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for ARPO stock?
The Revenue of Aerpio Pharmaceuticals Inc (ARPO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ARPO stock?
Aerpio Pharmaceuticals Inc (ARPO) has a market capitalization of 104.85M null. This makes ARPO a Micro Cap stock.